MicroPort Scientific Corporation

DB:MSK Stock Report

Market Cap: €1.4b

MicroPort Scientific Valuation

Is MSK undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MSK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: MSK (€0.75) is trading below our estimate of fair value (€1.71)

Significantly Below Fair Value: MSK is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MSK?

Key metric: As MSK is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for MSK. This is calculated by dividing MSK's market cap by their current revenue.
What is MSK's PS Ratio?
PS Ratio1.4x
SalesUS$1.03b
Market CapUS$1.48b

Price to Sales Ratio vs Peers

How does MSK's PS Ratio compare to its peers?

The above table shows the PS ratio for MSK vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.8x
EUZ Eckert & Ziegler
3.1x6.0%€838.4m
DRW3 Drägerwerk KGaA
0.2x4.2%€799.5m
AFX Carl Zeiss Meditec
2.5x7.9%€5.3b
SBS Stratec
1.4x7.7%€354.3m
MSK MicroPort Scientific
1.4x15.3%€11.5b

Price-To-Sales vs Peers: MSK is good value based on its Price-To-Sales Ratio (1.4x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does MSK's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.2x4.2%US$840.47m
PHH2 Paul Hartmann
0.3xn/aUS$735.59m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
MSK 1.4xIndustry Avg. 3.5xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: MSK is good value based on its Price-To-Sales Ratio (1.4x) compared to the European Medical Equipment industry average (3.5x).

Price to Sales Ratio vs Fair Ratio

What is MSK's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MSK PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.4x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: MSK is good value based on its Price-To-Sales Ratio (1.4x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MSK forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€0.75
€1.07
+42.8%
52.5%€2.52€0.69n/a8
Nov ’25€0.74
€1.05
+40.3%
52.8%€2.47€0.68n/a8
Oct ’25€0.89
€1.03
+15.3%
52.6%€2.42€0.67n/a8
Sep ’25€0.56
€1.35
+140.6%
55.0%€2.78€0.77n/a8
Aug ’25€0.60
€1.38
+128.8%
54.9%€2.86€0.79n/a8
Jul ’25€0.61
€1.45
+137.2%
51.0%€2.88€0.80n/a8
Jun ’25€0.69
€1.49
+117.1%
55.2%€2.94€0.79n/a8
May ’25€0.73
€1.60
+119.2%
54.1%€3.00€0.81n/a7
Apr ’25€0.76
€1.66
+119.6%
49.1%€2.97€0.86n/a8
Mar ’25€0.86
€2.00
+132.0%
36.4%€2.97€1.00n/a8
Feb ’25€0.66
€2.10
+220.3%
29.4%€2.94€1.12n/a8
Jan ’25€0.92
€2.25
+144.1%
24.2%€2.97€1.13n/a8
Dec ’24€1.40
€2.28
+62.9%
24.2%€3.01€1.15n/a8
Nov ’24€1.40
€2.28
+62.9%
24.2%€3.01€1.15€0.748
Oct ’24€1.40
€2.28
+62.9%
24.2%€3.01€1.15€0.898
Sep ’24€1.51
€2.57
+70.5%
28.4%€3.57€1.12€0.569
Aug ’24€1.70
€2.68
+57.8%
26.7%€3.50€1.11€0.609
Jul ’24€1.58
€2.88
+82.5%
26.0%€3.76€1.11€0.619
Jun ’24€1.59
€2.93
+84.3%
20.5%€3.74€1.68€0.699
May ’24€1.93
€2.96
+53.2%
20.5%€3.77€1.69€0.739
Apr ’24€2.08
€2.97
+42.7%
19.0%€3.80€1.83€0.769
Mar ’24€2.60
€3.06
+17.7%
19.8%€3.90€1.88€0.868
Feb ’24€2.96
€2.80
-5.2%
18.7%€3.56€1.85€0.668
Jan ’24€2.38
€3.20
+34.3%
48.8%€7.04€1.90€0.928
Dec ’23€2.26
€3.22
+42.3%
48.8%€7.09€1.90€1.408
Nov ’23€2.10
€3.35
+59.5%
51.7%€7.54€1.50€1.408

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Ship Healthcare Holdings

JP¥195.0b

Engages in the medical, healthcare, welfare, and nursing care businesses worldwide.

5EZ

JP¥12.20

7D

-11.6%

1Y

-5.4%

Sensus Healthcare

US$112.8m

A medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide.

5TX

US$6.45

7D

4.0%

1Y

251.1%

Shandong Weigao Group Medical Polymer

HK$21.2b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.55

7D

-13.5%

1Y

-39.1%